Connect with us

News

Genea Biomedx and Future Fertility develop scientific partnership to streamline oocyte quality assessment and improve clinical outcomes in fertility labs

Future Fertility’s oocyte tools will be available for automatic integration within the Geri Time-lapse incubator

Published

on

Future Fertility’s new integration with Genea Biomedx’s Geri time-lapse incubators enables labs to seamlessly generate personalised oocyte quality reports for patients, adding to Geri’s proven ability to improve clinical outcomes and efficiency.

On the heels of a recent acquisition by Basecare, Genea Biomedx, manufacturer of medical devices for IVF laboratories including Geri, the world-first and world’s only humidified time-lapse incubator, announced a strategic scientific partnership with Future Fertility, the global leader in oocyte assessment tools.

Future Fertility’s oocyte tools will be available for automatic integration within the Geri Time-lapse incubator as an optional value-added feature for Geri clients globally.

With over two thirds of fertility cycles failing on average globally, it is critical for clinicians and embryologists to understand all variables and to use top-quality medical devices for all stages of the process.

While it is well understood that the oocyte plays a critical role in embryo development, there is no current standard of care for oocyte assessment, which leaves embryologists and physicians to rely upon age and number of mature eggs to estimate egg quality.

Validated in over eight regions, live in over 15 countries and used in over 70 clinics globally, Future Fertility’s AI tools empower patients and clinicians to make more informed decisions along the IVF journey.

Validation studies have demonstrated an approximate 20 per cent improvement over embryologist assessments, and a 100 per cent repeatability rate in predictions.

Studies have also proven a strong correlation between Magenta scores and embryo quality, with scores outperforming prediction models built based on age alone, demonstrating the importance of personalised oocyte assessments and their role in clinical practice.

Geri has an established presence in over 600 laboratories globally and its use resulted in statistically significant improvements in embryo development and clinical outcomes, including a 24 per cent increased clinical pregnancy rate, in comparison to a conventional culture system.

As the world’s only humidified time-lapse incubator and with individualized patient culture, Geri presents a premium offering to laboratories aiming to achieve the best quality embryos and the fastest time to pregnancy.

Integration between Future Fertility and Geri enables clinics to pull oocyte AI reports in real-time, saving the clinic time as images are automatically collected in the background from Geri. This streamlines lab processes, simplifying access to oocyte assessments which are available in as little as three seconds.

Geri customers will benefit from hands-off software set-up and improved lab efficiency, in addition to an enhanced patient experience from the patient-friendly counselling reports, complementing Geri’s ability to bring greater efficiency via remote monitoring and automated annotation of embryos.

“The importance of choosing the right tools to culture and select embryos has never been more obvious, and AI-powered decision support tools are emerging as a new standard of care in fertility treatments,” said Tom Beckitt, COO of Genea Biomedx.

“In our company’s commitment to developing fertility technologies that improve clinical outcomes, the integration of Future Fertility’s clinically validated oocyte assessment software alongside Geri Connect & Geri Assess provides our customers not only with lab efficiencies, but also new AI-powered insights that were not previously observable by embryologists alone.”

Future Fertility’s CEO, Christy Prada, expressed her excitement about this innovative partnership, stating: “We’re thrilled to collaborate to streamline embryologists’ workflows and deliver more value to their ICSI IVF patients through easy access to our personalised oocyte quality reports.

“Genea Biomedx’s commitment to quality is evidenced through their uniquely designed Geri time-lapse incubator, and we are grateful to partner with a leader in the field.”

Fertility

Toxins and climate harms having ‘alarming’ effect on fertility, research warns

Published

on

Simultaneous exposure to toxic chemicals and climate-related heat may be worsening fertility harms across humans and wildlife, research suggests.

The review of scientific literature looks at how endocrine-disrupting chemicals, often found in plastic, together with climate-related effects such as heat stress, are each linked to lower fertility and fecundity, meaning the ability to reproduce, across species including humans, wildlife and invertebrates.

Though the reproductive harms of each issue in isolation are well studied, there is little research on what happens when living organisms are exposed to both.

“Together, the two issues are likely to pose a greater threat to fertility, and the additive effect is “alarming”, said Susanne Brander, a study lead author and courtesy faculty at Oregon State University.

“You’re not just getting exposed to one, but two, stressors at the same time that both may affect your fertility, and in turn the overall impact is going to be a bit worse,” Brander said.

The paper looked at 177 studies.

Shanna Swan, a co-author on the new paper, co-produced a 2017 study that found sperm levels among men in western countries had fallen by more than 50 per cent over four decades. Other research has suggested human fertility has been declining at a similar rate.

The University of Washington’s Institute for Health Metrics and Evaluation has previously said the world was approaching a “low-fertility future”, with more than three quarters of countries below replacement rate by 2050.

The new paper’s authors focused on the effects of endocrine-disrupting chemicals and substances, including microplastics, bisphenol, phthalates and PFAS.

These are thought to cause a range of serious reproductive problems, disrupt hormones and be a potential driver of falling fertility.

Brander said the harms linked to these chemicals are often similar across organisms, from invertebrates to humans.

Phthalates, for example, have been linked to altered sperm shape in invertebrates, spermatogenesis in rodents, meaning sperm production, and reduced sperm counts in humans.

PFAS are also thought to affect sperm quality, and both have been linked to hormone disruption.

The chemicals are widespread in consumer goods, so people are often regularly exposed.

Meanwhile, previous research has shown how rising temperatures, lower oxygen levels and heat stress, among other effects linked to climate change, may also worsen infertility.

Heat stress has been found to affect human hormones, and is linked to spermatogenesis in rodents and bulls.

Research shows temperature also plays a role in sex determination in fish, reptiles and amphibians.

The species has evolved to choose which sex it produces in part based on temperature, and the heating planet can “push it too far in one direction or the other, which overrides that evolutionary benefit”, Brander said.

Similarly, many endocrine disruptors may alter environmental sex determination.

The study set out some of the overlapping effects of chemical exposure and climate change across taxonomic groups, from invertebrates to humans.

In birds, for example, exposure to increased temperature, PFAS, organochlorines and pyrethroids may each individually cause abnormal sperm, increased fledgling mortality, abnormal testes and population decline.

“What happens if they’re exposed to more than one of those stressors at the same time? There has been little exploration of that question.

“Even if there have not been a lot of studies looking at these simultaneously, if you have two different factors that both cause the same adverse effect, then there’s a likelihood that they are going to be additive,” Brander said.

Katie Pelch, a senior scientist with the Natural Resources Defense Council nonprofit, who was not part of the study, said the authors had reviewed high-quality science.

She said she wanted to see more examples of the overlap in impacts, but agreed with the overall premise.

“It is likely [multiple stressors] would have an additive effect, at very least, even if they have different mechanisms of harm,” Pelch added.

The solution to the systemic problems would involve tackling climate change and reducing the use of toxic chemicals.

The study cites the global reduction in the use of DDT and PCBs achieved under the Stockholm Convention as an example of an effective measure, but Brander said much more is needed.

“There is enough evidence in both areas to act to reduce our impact on the planet,” she said.

Continue Reading

Pregnancy

Home blood pressure checks could lower heart risks for new mothers – study

Published

on

Home blood pressure checks after hypertensive pregnancy could cut the risk of heart attack, stroke and potentially early death, research suggests.

Women who regularly monitored their blood pressure in the weeks after giving birth, and had doctors tailor their medication if needed, had better functioning arteries nine months later than those who received routine care.

When the medication was adjusted to account for blood pressure changes, the women ended up with less stiff arteries, an effect researchers estimated could reduce the future risk of heart attack or stroke by 10 per cent.

Paul Leeson, professor of cardiovascular medicine who led the study, said the findings suggested that the weeks after birth provided a “powerful and often overlooked opportunity” to protect women’s future health.

“By simply monitoring blood pressure at home, new mothers with hypertensive pregnancies can protect their bodies from future damage,” he said.

High blood pressure, in the form of gestational hypertension or pre-eclampsia, where there are signs of organ damage, affects 5 to 10 per cent of pregnant women.

The condition can damage the mother’s organs and endanger the baby’s life.

Beyond the immediate threat to mother and baby, hypertension in pregnancy can raise the risk of long-term problems, with women three times more likely to develop high blood pressure and twice as likely to have heart disease later in life.

The Oxford team recruited 220 women who developed hypertension in pregnancy. All were on blood pressure medication but were due to reduce their dosage and eventually stop taking the drugs.

In the study, 108 women had standard care in which their medication was reduced based on a few blood pressure checks in the eight weeks after giving birth.

The remaining 112 women used a monitor to check their blood pressure at home each day.

They entered the readings into an app shared with doctors who, if needed, changed their medication day to day, with the aim of giving them better control of their blood pressure.

The new approach led to much better control of the women’s blood pressure, and in tests six to nine months later the women had less stiff arteries.

Stiff arteries are less effective at expanding and contracting, which can drive high blood pressure and ultimately the formation of clots that can block blood vessels and cause heart attacks and strokes.

Trials are now under way to find effective ways of rolling out blood pressure monitoring to women after hypertensive pregnancies. One option is for specialist NHS clinics to deliver the care.

Dr Sonya Babu-Narayan, clinical director at the British Heart Foundation, which funded the work, said the results highlighted a crucial window after birth when paying close attention to blood pressure could help protect women’s heart health for years to come.

“We now look forward to seeing results from larger studies with longer follow-up to see how this might save women’s lives,” she said.

Continue Reading

Fertility

Researcher explores weight loss jab impact on PCOS

Published

on

Weight loss jabs are being studied to see if they could help women with polycystic ovary syndrome (PCOS)

The condition, which affects up to one in ten women, changes how the ovaries work and is linked to infertility and weight gain.

Dr Shagaf Bakour has won a £60,000 NHS research grant through Sandwell and West Birmingham NHS Trust to look at whether drugs such as Mounjaro and Ozempic might help.

“The research could lead to earlier support, better long-term health, and more joined-up care for a condition that affects many women but is still often overlooked,” she said.

Women with PCOS have higher levels of male hormones and can suffer from irregular periods and symptoms such as excess body or facial hair, the NHS said.

Associated weight gain can also lead to an increased risk of diabetes and heart problems.

Bakour, a gynaecologist and director of medical education at Aston Medical School, will work with a team to evaluate the effect of the weight loss medicines on metabolic and reproductive outcomes.

The drugs mimic a hormone called GLP-1, which suppresses appetite.

Bakour, alongside Dr Hoda Harb, a consultant obstetrician and gynaecologist at the NHS trust, will review existing evidence on their use and assess how they help patients with PCOS.

“The aim is to give women with PCOS evidence-informed, clearer treatment options and more consistent care,” she said.

“The project hopes to show whether these medicines can improve both general health and fertility health, while also helping local services develop clearer care pathways.

Prof Elizabeth Hughes, director of research and development at the NHS trust, said the effects of PCOS, including infertility, were “very emotive subjects”.

“We should be doing all we can within research and development to advance healthcare for women and to better help future generations with this condition,” she added.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.